Can Chronic Myelomonocytic Leukemia (CMML) cause renal failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, Chronic Myelomonocytic Leukemia (CMML) can cause renal failure through several mechanisms. CMML is a hematologic malignancy that causes abnormal proliferation of monocytes and can infiltrate various organs, including the kidneys. Renal failure in CMML patients may occur due to direct leukemic infiltration of the kidneys, which disrupts normal kidney structure and function. Additionally, CMML can cause hyperviscosity syndrome from high white blood cell counts, leading to impaired blood flow to the kidneys. Tumor lysis syndrome may develop during treatment, releasing cellular contents that overwhelm the kidneys. CMML patients often experience thrombotic microangiopathy, where small blood vessels in the kidneys become damaged.

Key Mechanisms of Renal Failure in CMML

  • Direct leukemic infiltration of the kidneys
  • Hyperviscosity syndrome
  • Tumor lysis syndrome
  • Thrombotic microangiopathy

Monitoring and Treatment

Patients with CMML should have regular kidney function monitoring through blood tests measuring creatinine and BUN levels, and urinalysis to detect proteinuria or hematuria. Treatment of CMML-related kidney dysfunction focuses on addressing the underlying disease with hypomethylating agents like azacitidine or decitabine, while maintaining adequate hydration and avoiding nephrotoxic medications when possible 1.

Recent Guidelines and Recommendations

Recent studies and guidelines, such as those from the European LeukemiaNet 1 and the NCCN Clinical Practice Guidelines in Oncology 1, emphasize the importance of managing CMML with a focus on preventing and treating complications, including renal failure. The use of hypomethylating agents and other targeted therapies has shown promise in improving outcomes for CMML patients, including those with renal involvement 1.

Conclusion Not Applicable - Direct Answer Only

The most recent and highest quality study, 1, supports the use of hypomethylating agents in the treatment of CMML, including for patients with renal involvement.

From the Research

CMML and Renal Failure

  • Chronic Myelomonocytic Leukemia (CMML) is a hematologic disorder that can be associated with autoimmune and inflammatory diseases, including renal complications 2.
  • Studies have shown that CMML can cause renal failure, with kidney involvement being a common feature of the disease 2, 3.
  • The renal complications of CMML can be direct or indirect, including prerenal azotemia, glomerular disease, tubulointerstitial involvement, and renovascular disorders 3.

Mechanisms of Renal Failure in CMML

  • Lysozyme nephropathy and renal infiltration by CMML cells are two of the most frequent renal complications of CMML 2.
  • Hyperuricemia and uric acid nephropathy can also contribute to renal failure in CMML patients 4.
  • Renal dysfunction in CMML can be attributed to various factors, including hyperlysozymemia, leukemic infiltration, and secondary diseases 5.

Clinical Presentations and Outcomes

  • CMML patients with renal involvement may present with acute kidney injury, chronic kidney disease, or end-stage kidney disease 2, 4.
  • The prognosis of CMML patients with renal involvement is generally poor, with a high risk of progression to acute myeloid leukemia (AML) and mortality 2, 4.
  • Treatment of CMML-related renal complications may involve hematologic therapies, such as hydroxyurea or hypomethylating agents, as well as supportive care for renal failure 2, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Transformation of CMML to AML presenting with acute kidney injury.

Journal of community hospital internal medicine perspectives, 2020

Research

Pathoanatomical features of the kidney in myelomonocytic and chronic lymphocytic leukemia.

Virchows Archiv. A, Pathological anatomy and histology, 1975

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.